Search Results

The Departments of Neurosurgery and Nuclear Medicine at the University Hospital Münster, Helmholtz Munich, and ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced that the first patient has been dosed in an investigator-initiated trial with ITM’s radiopharmaceutical drug candidate, ITM-31 for the potential use in glioblastoma patients.

ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, Helmholtz Munich and the Departments of Neurosurgery and Nuclear Medicine at the University Hospital Münster announced the start of a Phase I clinical trial with ITM’s drug candidate ITM-31, a novel Targeted Radionuclide Therapy candidate for the treatment of malignant glioblastoma.

Biocrates Life Sciences AG, the global leader in targeted metabolomics, and Helmholtz Zentrum München, the German Research Center for Environmental Health, enter a new phase of collaboration in their 10-year partnership.

Phio Pharmaceuticals Corp. announced that is has entered into a research collaboration with the Helmholtz Zentrum München.

ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, and Helmholtz Munich, announced a cooperation agreement for the clinical development of a radiopharmaceutical therapy candidate to treat malignant brain tumor glioblastoma.

Phio Pharmaceuticals Corp. today announced that its research partner, Helmholtz Munich, presented preclinical data showing that Phio’s lead clinical product PH-762.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that it has reached a new agreement with Medigene AG (“Medigene”) in relation to

The Helmholtz Association is funding a new Helmholtz Zentrum München spin-off with roughly 115,000 euros.

Glycotope GmbH and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association have signed an agreement to explore the potential of combining Glycotope’s antibodies against protein/carbohydrate combined glyco-epitopes with chimeric antigen receptor technology developed by the Max Delbrück Center.